Pivotal Study for the FLAIR Endovascular Stent Graft
A Prospective, Multi-Center, Randomized Evaluation of an IMPRA/Bard ePTFE Encapsulated Carbon Lined Nitinol Endoluminal Device for AV Access Graft Stenoses
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- New York Presbyterian Hospital/Columbia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients between 18 to 90 years of age whose hemodialysis access was a synthetic AV access graft located in an arm.
- Angiographic evidence of one or more stenoses, 7 cm or less in length and greater than or equal to 50%, at the graft-vein anastomosis of a synthetic AV access graft. The entire lesion must have been located within 7 cm of the anastomosis such that approximately 1 cm of the IMPRA/Bard Device must have extended into non-diseased vein and approximately 1 cm, but no more than 2 cm, of the IMPRA/Bard Device will be extended into non-diseased AV graft.
- Clinical evidence of a hemodynamically significant stenosis.
- Percutaneous endovascular therapy for the identified lesion was the best treatment choice in the opinion of the investigator.
- Patients must have been able to understand and provide informed consent.
- Patients whose synthetic AV access grafts had been implanted greater than 30 days and had undergone 1 or more successful hemodialysis sessions.
- During primary balloon angioplasty, full expansion of an appropriately sized angioplasty balloon, in the operator's judgment, must have been achieved.
Exclusion Criteria:
- Concomitant disease (e.g., terminal cancer) or other medical condition that was likely to result in death of the patient within 6 months of the time of implantation.
- Stenoses that had a corresponding thrombosis treated within 7 days.
- The presence of a second lesion in the access circuit less than or equal to 3 cm from the edges of the primary lesion that was treated within 30 days or that was greater than or equal to 30%. Access circuit was defined as the area from the AV access graft arterial anastomosis to the superior vena cava-right atrial junction.
- The presence of a second lesion in the access circuit greater than 3 cm from the edges of the primary lesion that was greater than or equal to 30%. Second lesions that were greater than or equal to 30% must have been treated prior to patient inclusion to reduce the percent stenosis to less than 30%.
- Patients who were unwilling or unable to return for follow-up visits or patients with whom follow-up visits may have been unreliable.
- Patients who had a stent placed at the target lesion site.
- Patients with a blood coagulative disorder or sepsis.
- Patients in which the IMPRA/Bard Device would have been required to cross an angle (between the inflow vein and synthetic AV access graft) that was greater than 90 degrees.
- Patients in which the IMPRA/Bard Device would have been required to be deployed fully across the elbow joint, which is identified radiographically by a combination of the humeroulnar joint and the humeroradial joint.
- Patients with a contraindication to the use of contrast media.
- Patients whose AV access graft was infected.
- Patients who were currently or were scheduled to enroll in other investigations that conflicted with follow-up testing or confounds data in this trial.
- Procedural use of another investigational device.
- Patients who were pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: FLAIR
Primary PTA followed by placement of the FLAIR Endovascular Stent Graft
|
Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
Other Names:
Primary PTA followed by placement of the FLAIR Endovascular Stent Graft.
Roll-in participants were enrolled in the study for training purposes and were not randomized.
Other Names:
|
|
Active Comparator: PTA Only
Percutaneous Transluminal Angioplasty
|
Percutaneous Transluminal Angioplasty
Other Names:
|
|
Experimental: FLAIR Roll-in Participants
Primary Patency followed by placement of the FLAIR Endovascular Stent Graft.
Roll-in participants were enrolled in the study for training purposes and were not randomized.
|
Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
Other Names:
Primary PTA followed by placement of the FLAIR Endovascular Stent Graft.
Roll-in participants were enrolled in the study for training purposes and were not randomized.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent of Participants With Treatment Area Primary Patency (TAPP)
Time Frame: 6 month follow-up
|
TAPP was defined as patency (open to blood flow) after the study index procedure until reintervention in the treatment area (within 5 mm proximal or 5 mm distal to the study device or index balloon angioplasty treatment area), or thrombotic occlusion that involved the treatment area.
|
6 month follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Number of Adverse Events
Time Frame: 6 month Follow-Up
|
The safety endpoint was evaluated based on the incidence of adverse events observed within the same time interval.
An adverse event was defined as any undesirable clinical occurrence in a patient that (a) is considered possibly or definietly device related by the investigator, (b) involves the access circuit (AV graft arterial anastomosis to the superior vena cava-right atrial junction) or the arm where the access circuit is located or (c) the investigator considers relevant to the objectives of this study.
An adverse event could be mild, moderate or severe.
|
6 month Follow-Up
|
|
Percent of Participants With Successful Delivery of the Device
Time Frame: Index Procedure
|
The ability to successfully deliver the FLAIR™ Endovascular Stent Graft.
Successful delivery is the ability to deliver and seat the implant in the intended location of a stenosed segment of the venous anastomosis region of a synthetic access graft.
This attribute is only applicable to the FLAIR and FLAIR Roll-in arms.
|
Index Procedure
|
|
Percent of Participants With Procedural Success
Time Frame: Index Procedure
|
Procedural Success was defined as anatomic success (<30% residual stenosis) and at least one indicator of hemodynamic or clinical success
|
Index Procedure
|
|
Percent of Participants With TAPP
Time Frame: 2 month Follow-Up
|
TAPP was defined as patency (open to blood flow) after the study index procedure until reintervention in the treatment area (within 5 mm proximal or 5 mm distal to the study device or index balloon angioplasty treatment area), or thrombotic occlusion that involved the treatment area.
|
2 month Follow-Up
|
|
Percent of Participants With Access Circuit Primary Patency (ACPP)
Time Frame: 6 month Follow-Up
|
ACCP defined as patency (open to blood flow) following the index study procedure until access thrombosis or an intervention of a lesion anywhere within the access circuit.
|
6 month Follow-Up
|
|
Percent of Participants With Access Circuit Assisted Primary Patency (ACAPP)
Time Frame: 6 month Follow-Up
|
ACAPP defined as patency (open to blood flow)following the index study procedure until access thrombosis or a surgical intervention that excludes the treated lesion from the access circuit.
|
6 month Follow-Up
|
|
Percent of Participants With Access Circuit Cumulative Patency (ACCP or Secondary Patency)
Time Frame: 6 month Follow-Up
|
ACCP defined as patency (open to blood flow) following the index study procedure until the access is surgically revised or abandoned because of the inability to treat the original lesion.
Multiple treatments for occlusions to restore patency are compatible with ACCP.
|
6 month Follow-Up
|
|
Percent of Participants With Binary Restenosis
Time Frame: 6 month Follow-Up
|
Binary restenosis defined as lesions with greater than or equal to 50% diameter stenosis of the treatment area (calculated by a core lab).
|
6 month Follow-Up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: David Ciavarella, MD, C. R. Bard
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IMP-9809
- P060002 (Other Identifier: Food and Drug Administration)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.